Drug Truths: Dispelling The Myths About Pharma R & D

This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.

John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.

This book, a concise and reasonably priced text, is a must-read for anyone working in the pharmaceutical industry. However, it is not just written for scientist, anyone interested in learning more about the big issues facing pharmaceutical research and development and global healthcare today should find this book thought-provoking. (Pharmaceutical Journal, September 2009)
Drug Truths: Dispelling the Myths About Pharma R & D is an generally persuasive argument for the soul of the pharmaceutical industry. (Journal of Clinical Research Best Practices, December 2009)
"I would recommend this book." (Chemistry World, June 2009)
"LaMattina stands out from many of the other observers of the industry." (Nature Chemistry, May 2009)
"The book provides unique insights into how big pharma manages its R&D. It also serves as a reminder of the useful role the drug industry play in keeping us healthy." (Chemical & Engineering News, April 20, 2009)
The book offers an insider s account of the reality of the drug discovery process revealing it to be more risky, complicated and expensive than many critics suggest. Chapter by chapter, LaMattina addresses the common misconceptions about the pharmaceutical industry setting the record straight. (Kansas City InfoZine, February 2009)
Along with a careful dissection of each false claim and a presentation of the overwhelming evidence that disproves it, LaMattina offers fascinating explanations of the way drug development and government approval function relying not on clever rhetoric, but on scientific fact and reliable evidence to support his claims; all the while remaining realistic about the industry's limitations. (Medical News Today, February 2009)
"It's obvious from reading his book that LaMattina believes in his industry, in Big Pharma, and in the research and development that has led to drugs that have cured infectious diseases, delayed encroaching heart disease, controlled arthritis for many millions reduced pain and suffering." (TheDay.com, January 25, 2009)
"John L. LaMattina … the recently retired head of Pfizer’s global research and development… by using well illustrated examples, takes us through the realities and myths about many of the issues surrounding the pharmaceutical industry. Rather than innuendo, he offers data. This is an important and timely book … In the end this book is about science where data rules. … [and] should become indispensable to those who wish to either understand or set policy."
—Dr. Richard A. Lerner, President of The Scripps Research Institute
"Drug Truths is an authoritative, clear and accessible exposition of the realities of drug discovery and development. It is factual and balanced, although LaMattina does not shy away from criticizing some of the misguided views that have appeared in print. The main points are well documented and logically presented. The book is a splendid addition to the contemporary health care literature."
—E. J. Corey, Harvard University

Acknowledgments.
Introduction.
PART 1: A MATTER OF THE HEART.
Chapter 1: Cholesterol Drugs Are Unnecessary.
Chapter 2: Industry is More Interested in "Me-Too" Drugs Than in Innovation.
Chapter 3: It Takes Industry Too Long to Discover New Drugs.
PART 2: THE ROLE OF PHARMACEUTICAL R&D IN HEALTHCARE.
Chapter 4: Drugs Are Discovered by Academia.
Chapter 5: New Medicines Add Costs but Little Benefit.
Chapter 6: Big Pharma Has Failed and Should Learn From Biotech Success.
PART 3: THE PROFIT MOTIVE.
Chapter 7: The Industry Invents Diseases.
Chapter 8: New Drugs Are Less Safe Than Traditional Medicines.
Chapter 9: Industry Spends More on Advertising Than R&D.
Chapter 10: Industry Does Not Care About Diseases of the Developing World.
PART 4: THE FUTURE.
Chapter 11: Big Pharma’s Day Has Passed.
Chapter 12: Final Reflections.
References.
Index.